Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolving Role of Viltolarsen for Treatment of Duchenne Muscular Dystrophy

20 Feb 2024

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiomyopathy and Myosin Studies
Share to Muscle Physiology and Disorders
Share to Telomeres, Telomerase, and Senescence

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 38376743
DOI: 10.1007/s12325-024-02801-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolving Role of Viltolarsen for Treatment of Duchenne Muscular DystrophyPMID 38376743Read ↗

Evolving Therapeutic Options for the Treatment of Duchenne Muscular DystrophySemantic proximity Read ↗

Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging PharmacotherapiesSemantic proximity Read ↗

Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the lineSemantic proximity Read ↗

Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future.Semantic proximity Read ↗

Therapeutic Approaches for Duchenne Muscular Dystrophy: Old and NewSemantic proximity Read ↗

Opinion of the Italian Association of Myology on Ataluren for the Treatment of Nonsense Mutation Duchenne Muscular DystrophySemantic proximity Read ↗

Emerging drugs for Duchenne muscular dystrophySemantic proximity Read ↗

Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular DystrophySemantic proximity Read ↗

Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1/2 studySemantic proximity Read ↗

European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin geneSemantic proximity Read ↗

Pharmacological prospects in the treatment of Duchenne muscular dystrophy.Semantic proximity Read ↗

Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.